Ataxia
Sep 22, 2026
Novo’s CagriSema Shows Greater Weight Loss Than Tirzepatide in REIMAGINE 5 Trial; Telix and ITM Partner to Build a Radiopharmaceutical Powerhouse; Beacon Therapeutics Reveals Positive Topline Findings from VISTA Trial of Laru-zova for XLRP; FDA Clears Inluriyo in Combination with Verzenio for Adults with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer; IntraBio Announces FDA Approval of AQNEURSA for Ataxia-Telangiectasia
Novo’s CagriSema Demonstrates Superior Weight Loss Over Tirzepatide in REIMAGINE 5 Novo Nordisk announced topline results from the Phase 3 REIMAGINE 5 and REDEFINE 9 trials evaluating once-weekly CagriSema (cagrilintide and semaglutide), an investigational therapy and the company’s next-generation approach to we...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
